Cover Image
市場調查報告書

無針注射器:醫療設備的開發平台評估

Needle Free Injections - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 357852
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
無針注射器:醫療設備的開發平台評估 Needle Free Injections - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年07月18日 內容資訊: 英文 141 Pages
簡介

本報告提供無針注射器相關的開發中產品之相關調查,提供各開發階段趨勢和產品的主要開發企業,現在持續中臨床實驗,產業的近幾年趨勢等資訊。

第1章 目錄

第2章 簡介

  • 無針注射器概要

第3章 開發中的產品

  • 無針注射器 - 開發中產品:各開發階段
  • 無針注射器 - 開發中產品:地區 (國家) 各
  • 無針注射器 - 開發中產品:各法規途徑
  • 無針注射器 - 開發中產品:各核准時期 (估計)

第4章 無針注射器 - 正在開發的開發中產品:各企業

  • 無針注射器企業 - 開發中產品:各開發階段
  • 無針注射器 - 開發中產品:各開發階段

第5章 無針注射器 開發企業與產品概要

  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • Crossject SA
  • Enable Injections, LLC
  • Eternity Healthcare Inc.
  • EuroJet Medical Kft.
  • Glide Pharmaceutical Technologies Limited
  • Inovio Pharmaceuticals Inc
  • Medical International Technologies (Mit Canada) Inc.
  • PharmaJet, Inc.
  • Teva Pharmaceutical Industries Limited

第6章 無針注射器 - 近幾年趨勢

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0379EPD

GlobalData's Medical Devices sector report, "Needle Free Injections - Medical Devices Pipeline Assessment, 2017" provides an overview of Needle Free Injections currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Needle Free Injections pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Needle Free Injections under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Needle Free Injections and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Needle Free Injections under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Needle Free Injections Overview 7

3 Products under Development 8

  • 3.1 Needle Free Injections - Pipeline Products by Stage of Development 8
  • 3.2 Needle Free Injections - Pipeline Products by Territory 9
  • 3.3 Needle Free Injections - Pipeline Products by Regulatory Path 10
  • 3.4 Needle Free Injections - Pipeline Products by Estimated Approval Date 11
  • 3.5 Needle Free Injections - Ongoing Clinical Trials 12

4 Needle Free Injections - Pipeline Products under Development by Companies 13

  • 4.1 Needle Free Injections Companies - Pipeline Products by Stage of Development 13
  • 4.2 Needle Free Injections - Pipeline Products by Stage of Development 14

5 Needle Free Injections Companies and Product Overview 15

  • 5.1 B. Braun Melsungen AG Company Overview 15
    • 5.1.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.2 Boston Scientific Corp Company Overview 16
    • 5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.3 Crossject SA Company Overview 17
    • 5.3.1 Crossject SA Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.4 Enable Injections, LLC Company Overview 21
    • 5.4.1 Enable Injections, LLC Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.5 Eternity Healthcare Inc. Company Overview 22
    • 5.5.1 Eternity Healthcare Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.6 EuroJet Medical Kft. Company Overview 23
    • 5.6.1 EuroJet Medical Kft. Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.7 Glide Pharmaceutical Technologies Ltd Company Overview 24
    • 5.7.1 Glide Pharmaceutical Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.8 Inovio Pharmaceuticals Inc Company Overview 25
    • 5.8.1 Inovio Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.9 Medical International Technologies (Mit Canada) Inc Company Overview 30
    • 5.9.1 Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.10 PharmaJet Inc Company Overview 35
    • 5.10.1 PharmaJet Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.11 Teva Pharmaceutical Industries Ltd Company Overview 39
    • 5.11.1 Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 39

6 Needle Free Injections- Recent Developments 40

  • 6.1 Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell 40
  • 6.2 Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 40
  • 6.3 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 40
  • 6.4 Jun 15, 2017: Consort Medical: Full year results 42
  • 6.5 Jun 13, 2017: Needle-free Injection Linked to Increasing Workplace Flu Shot Compliance 43
  • 6.6 Jun 08, 2017: B. Braun is participating in the third edition of the High-Tech Founders Fund 44
  • 6.7 Jun 06, 2017: Valeritas Appoints Peter J. Devlin to Chairman of its Board of Directors 44
  • 6.8 May 15, 2017: Aradigm Announces First Quarter 2017 Financial Results 45
  • 6.9 May 12, 2017: Valeritas Reports First Quarter 2017 Financial Results 45
  • 6.10 May 11, 2017: Teva Reports First Quarter 2017 Financial Results 46
  • 6.11 May 10, 2017: ICU Medical Announces First Quarter 2017 Results 50
  • 6.12 May 09, 2017: Antares Pharma Reports First Quarter 2017 Operating and Financial Results 51
  • 6.13 May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 53
  • 6.14 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 53
  • 6.15 Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 55
  • 6.16 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 56
  • 6.17 Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 57
  • 6.18 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 57
  • 6.19 Apr 12, 2017: Change in the B. Braun Management Board and the Aesculap Management Board 59
  • 6.20 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 59
  • 6.21 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 60
  • 6.22 Mar 31, 2017: B. Braun continues its sales and earnings growth 60
  • 6.23 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 62
  • 6.24 Mar 28, 2017: Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results 62
  • 6.25 Mar 14, 2017: Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results 64
  • 6.26 Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 65
  • 6.27 Mar 07, 2017: PharmaJet partners with Serum Institute to Launch Needle-Free MMR Vaccine 67
  • 6.28 Mar 06, 2017: CROSSJECT receives authorization to conduct Zeneo Midazolam bioequivalence study 67
  • 6.29 Mar 01, 2017: ICU Medical Announces Fourth Quarter and Fiscal Year 2016 Results 68
  • 6.30 Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 69
  • 6.31 Feb 24, 2017: Daiichi Sankyo Appoints New Group Corporate Officers 70
  • 6.32 Feb 22, 2017: Change in the B. Braun Management Board 71
  • 6.33 Feb 21, 2017: Valeritas Reports Fourth Quarter and Full Year 2016 Financial Results 71
  • 6.34 Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 72
  • 6.35 Feb 14, 2017: Expanded Vaccine offering for PharmaJet Needle-free Device 73
  • 6.36 Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 73
  • 6.37 Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure 80
  • 6.38 Feb 09, 2017: Terumo Announces Change of Executive Officers 80
  • 6.39 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 81
  • 6.40 Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 82
  • 6.41 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 84
  • 6.42 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 85
  • 6.43 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 87
  • 6.44 Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 90
  • 6.45 Jan 31, 2017: Terumo Opens a Branch in Yangon 90
  • 6.46 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 90
  • 6.47 Jan 10, 2017: Milestone Certification Achieved For Eternity Healthcare's Lenis Device 91
  • 6.48 Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System 92
  • 6.49 Jan 06, 2017: Teva Provides 2017 Financial Outlook 92
  • 6.50 Jan 05, 2017: Zogenix Announces CFO Transition 93
  • 6.51 Dec 22, 2016: Teva Reaches Settlement with Government on FCPA 95
  • 6.52 Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges 95
  • 6.53 Dec 14, 2016: Consort Medical: Directorate Change 96
  • 6.54 Dec 13, 2016: Eternity Healthcare Moves to Next Stage Regulatory Approval Phase with Lenis 96
  • 6.55 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy 97
  • 6.56 Dec 06, 2016: Consort Medical Reports Interim Results Results For The Six Months Ended 31 October 2016 97
  • 6.57 Dec 05, 2016: Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson 99
  • 6.58 Nov 30, 2016: Valeritas Elects Joe Mandato, Ph.D., Experienced Medical Device Executive and Investor, to Board of Directors 101
  • 6.59 Nov 25, 2016: Consort Medical: CFO Appointment 101
  • 6.60 Nov 15, 2016: Teva Reports Third Quarter 2016 Results 102
  • 6.61 Nov 14, 2016: BioSyent Pharma Launches New Urgent Care Product 104
  • 6.62 Nov 10, 2016: Valeritas Reports Third Quarter 2016 Financial Results 105
  • 6.63 Nov 09, 2016: Antares Pharma Reports Third Quarter 2016 Financial and Operating Results 106
  • 6.64 Nov 09, 2016: Aradigm Announces Third Quarter 2016 Financial Results 107
  • 6.65 Nov 09, 2016: ICU Medical Announces Third Quarter 2016 Results 108
  • 6.66 Nov 08, 2016: Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results 109
  • 6.67 Nov 08, 2016: Teva Announces Appointment of New Chief Legal Officer 110
  • 6.68 Oct 31, 2016: Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer 111
  • 6.69 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 112
  • 6.70 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 113
  • 6.71 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 115
  • 6.72 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 118
  • 6.73 Oct 04, 2016: PharmaJet Needle-Free Flu Shots Offered in Workplace Health Clinics 119
  • 6.74 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy 119
  • 6.75 Sep 22, 2016: Industry Veteran Katherine D. Crothall, PhD to Join Valeritas Board of Directors 120
  • 6.76 Sep 06, 2016: Daiichi Sankyo Announces New Global Head of Development 121
  • 6.77 Aug 30, 2016: PharmaJet Collaborates with World Health Organization 121
  • 6.78 Aug 17, 2016: Consort Medical Announces Directorate Change 122
  • 6.79 Aug 16, 2016: Valeritas Appoints Erick J. Lucera as Chief Financial Officer 122
  • 6.80 Aug 10, 2016: Aradigm Announces Second Quarter 2016 Financial Results 123
  • 6.81 Aug 10, 2016: Valeritas Reports Second Quarter 2016 Financial Results 124
  • 6.82 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results 125
  • 6.83 Aug 09, 2016: Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results 127
  • 6.84 Aug 08, 2016: ICU Medical Announces Second Quarter 2016 Results 128
  • 6.85 Aug 04, 2016: Teva Reports Second Quarter 2016 Results 128
  • 6.86 Aug 03, 2016: NIH using PharmaJet in DNA Vaccine Clinical Trial for Zika Virus 133
  • 6.87 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 134
  • 6.88 Jul 26, 2016: Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016 135

7 Appendix 138

  • 7.1 Methodology 138
  • 7.2 About GlobalData 141
  • 7.3 Contact Us 141
  • 7.4 Disclaimer 141

List of Tables

1.1 List of Tables

  • Table 1: Needle Free Injections - Pipeline Products by Stage of Development 8
  • Table 2: Needle Free Injections - Pipeline Products by Territory 9
  • Table 3: Needle Free Injections - Pipeline Products by Regulatory Path 10
  • Table 4: Needle Free Injections - Pipeline Products by Estimated Approval Date 11
  • Table 5: Needle Free Injections - Ongoing Clinical Trials 12
  • Table 6: Needle Free Injections Companies - Pipeline Products by Stage of Development 13
  • Table 7: Needle Free Injections - Pipeline Products by Stage of Development 14
  • Table 8: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 9: Needle-Free System - Product Status 15
  • Table 10: Needle-Free System - Product Description 15
  • Table 11: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16
  • Table 12: JetTouch System - Overactive Bladder - Product Status 16
  • Table 13: JetTouch System - Overactive Bladder - Product Description 16
  • Table 14: Crossject SA Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 15: Zeneo ID Human Needle-Free Injection Device - Product Status 17
  • Table 16: Zeneo ID Human Needle-Free Injection Device - Product Description 18
  • Table 17: Zeneo IM 0.5ml Needle - Free Injection Device - Product Status 18
  • Table 18: Zeneo IM 0.5ml Needle - Free Injection Device - Product Description 18
  • Table 19: Zeneo SC 0.5ml Needle-Free Injection Device - Product Status 19
  • Table 20: Zeneo SC 0.5ml Needle-Free Injection Device - Product Description 19
  • Table 21: Zeneo SC 0.8ml Needle-Free Injection Device - Product Status 19
  • Table 22: Zeneo SC 0.8ml Needle-Free Injection Device - Product Description 20
  • Table 23: Zeneo SC High Viscosity Needle-Free Injection Device - Product Status 20
  • Table 24: Zeneo SC High Viscosity Needle-Free Injection Device - Product Description 20
  • Table 25: Enable Injections, LLC Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 26: Enable Injector - Product Status 21
  • Table 27: Enable Injector - Product Description 21
  • Table 28: Eternity Healthcare Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 29: Multi Channel Needle-Free Injection Device - Product Status 22
  • Table 30: Multi Channel Needle-Free Injection Device - Product Description 22
  • Table 31: EuroJet Medical Kft. Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 32: E-Jet 500 Needle Free Injector - Product Status 23
  • Table 33: E-Jet 500 Needle Free Injector - Product Description 23
  • Table 34: Glide Pharmaceutical Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 35: Glide SDI - Product Status 24
  • Table 36: Glide SDI - Product Description 24
  • Table 37: Inovio Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 38: Iject R Pre-Filled Syringe - Product Status 25
  • Table 39: Iject R Pre-Filled Syringe - Product Description 26
  • Table 40: Intradermal Pen Injector - Product Status 26
  • Table 41: Intradermal Pen Injector - Product Description 26
  • Table 42: Intradermal Syringe - Product Status 27
  • Table 43: Intradermal Syringe - Product Description 27
  • Table 44: Mega Jet - Product Status 27
  • Table 45: Mega Jet - Product Description 28
  • Table 46: Multi-Port Orifices - Product Status 28
  • Table 47: Multi-Port Orifices - Product Description 28
  • Table 48: Needle-Free Vaccine Delivery Device - Product Status 29
  • Table 49: Needle-Free Vaccine Delivery Device - Product Description 29
  • Table 50: Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 51: MED-JET MBX Injector - Product Status 30
  • Table 52: MED-JET MBX Injector - Product Description 31
  • Table 53: MESO-JET - Product Status 31
  • Table 54: MESO-JET - Product Description 31
  • Table 55: MIT-H-III - Product Status 32
  • Table 56: MIT-H-III - Product Description 32
  • Table 57: MIT-H-IV-1 - Product Status 32
  • Table 58: MIT-H-IV-1 - Product Description 33
  • Table 59: MIT-H-IV-5 - Product Status 33
  • Table 60: MIT-H-IV-5 - Product Description 33
  • Table 61: MIT-H-VI Dental Injector - Product Status 34
  • Table 62: MIT-H-VI Dental Injector - Product Description 34
  • Table 63: PharmaJet Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 64: Tropis - Product Status 35
  • Table 65: Tropis - Product Description 35
  • Table 66: Variable Volume Drug Delivery Device - Product Status 36
  • Table 67: Variable Volume Drug Delivery Device - Product Description 36
  • Table 68: PharmaJet Inc - Ongoing Clinical Trials Overview 37
  • Table 69: Tropis - A Pragmatic Trial to Quantitatively and Qualitatively Assess Different Techniques for the ID Administration of Fractional Dose IPV in a Campaign Setting in the Gambia 38
  • Table 70: Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 71: MicroDose Needlefree System - Product Status 39
  • Table 72: MicroDose Needlefree System - Product Description 39
  • Table 73: Glossary 140

List of Figures

1.2 List of Figures

  • Figure 1: Needle Free Injections - Pipeline Products by Stage of Development 8
  • Figure 2: Needle Free Injections - Pipeline Products by Territory 9
  • Figure 3: Needle Free Injections - Pipeline Products by Regulatory Path 10
  • Figure 4: Needle Free Injections - Pipeline Products by Estimated Approval Date 11
  • Figure 5: Needle Free Injections - Ongoing Clinical Trials 12
Back to Top